Profile: Abiomed Inc (ABMD.O)

Abiomed Inc. is a provider of medical devices in circulatory support that offers a continuum of care in heart recovery to heart failure patients. The Company’s products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products can be used in a range of clinical settings, including by heart surgeons for patients in profound shock and by interventional cardiologists for patients who are in shock, pre-shock or in need of prophylactic support in the cardiac catheterization lab, or cath lab. Its circulatory care products are designed to provide hemodynamic support for acute patients from the cath lab to the surgery suite aimed towards heart recovery and sending the patient home with his or her native heart. The Company’s cardiac assist products provide circulatory support to acute heart failure patients across the continuum of care in heart recovery.

The Company’s BVS 5000 blood pump provides temporary left ventricular assist device (LVAD), right ventricular assist device (RVAD) or biventricular assist device (BiVAD) support until recovery for cardiogenic shock from heart attack; post-cardiotomy cardiogenic shock; myocarditis, failed transplant and certain other clinical instances where the physician believes heart recovery is possible. Its AB5000 Ventricle provides temporary LVAD, RVAD or BiVAD support until recovery for cardiogenic shock from heart attack: post-cardiotomy cardiogenic shock; myocarditis, failed transplant and certain other clinical instances where the physician believes heart recovery is possible; allows for full patient mobility. The Company’s Integrated Cannula System connects the BVS 5000 and AB5000 ventricle to the body, and provides an option for the removal of the devices without re-opening the chest. Its Impella LD provides temporary LVAD support for recovery from post-cardiotomy hemodynamic instability where the physician believes heart recovery is possible.

The Company’s Impella 2.5 provides miniature percutaneous heart pump providing up to 2.5 liters of blood flow per minute intended to support the heart while undergoing high-risk angioplasty procedures or for assisting the heart while in pre-shock for hemodynamic stabilization. Its Impella 5.0 provides percutaneous heart pump providing up to 5 liters of blood flow per minute for low cardiac output post-surgery patients intended to assist the heart while in pre-shock or profound shock for recovery. Its IAB Consoles provides percutaneous intra-aortic balloon used to support a variety of prophylactic, pre-shock and profound shock conditions. Its AB5000 Console is a driver console for both BVS 5000 Blood Pump and AB5000 Ventricle.

The Company’s Mobile Pump Console is a driver console for Impella products. Its The iPulse console is designed to support the Company’s AB5000 ventricle and BVS 5000 blood pump, other manufacturers’ IABs, and products it may offer in the future. The iPulse console is designed to support its IAB, as well as other manufacturers’ IABs, which are used in the cath lab and surgery suite. Designed to sustain the body’s circulation, the AbioCor is intended for end-stage biventricular heart failure patients whose other treatment options have been exhausted.

The Company competes with Thoratec Corporation, Arrow International, Jarvik Heart, HeartWare, World Heart Corporation, MicroMed Technology, Ventracor, EvaHeart and Terumo Heart.